The seemingly innocuous act of a minor fall has tragically highlighted a potentially life-threatening risk associated with common blood-thinning medication. A recent inquest in the United Kingdom has brought to light concerns regarding the clarity of safety information provided to patients taking apixaban, a widely prescribed anticoagulant, following the death of 64-year-old Clive Hyman. His widow, Rachel Hyman, is now urgently calling for improved warnings, believing her husband’s life could have been saved with greater awareness of the potential dangers following even a seemingly harmless head injury.
The case centers around apixaban, a medication frequently prescribed to prevent blood clots in individuals with conditions like atrial fibrillation or those recovering from heart attacks or strokes. Even as credited with saving countless lives, the drug carries a known risk of causing bleeding, particularly in the brain, if trauma occurs. The inquest revealed that the patient information leaflets accompanying apixaban did not explicitly advise patients on the crucial steps to accept if they sustained a head injury, a critical oversight that Assistant Coroner Sarah Bourke deemed a potential risk to future patients.
Clive Hyman, a former partner at KPMG and described as a highly intelligent and active individual, suffered a fall on marble steps in Bucharest, Romania, in August 2025 while on a phone call. Initially, he reported feeling “fine,” but nine days later, he tragically died in a London hospital after developing a brain hemorrhage. This case underscores the often-silent and delayed nature of bleeding complications associated with blood thinners, emphasizing the need for immediate medical attention even in the absence of apparent symptoms after a head injury. The incident has sparked a wider conversation about patient safety and the responsibility of pharmaceutical companies and healthcare providers to ensure clear and comprehensive medication guidance.
A Seemingly Minor Fall, A Devastating Outcome
According to reports from the inquest at Poplar Coroner’s Court, Clive Hyman was a man who prioritized his health. He regularly attended the gym five times a week and maintained a healthy diet. Despite this commitment to wellness, the fall proved fatal. The initial assessment following the incident suggested no immediate cause for concern, leading to a delay in seeking critical medical intervention. This delay, according to his widow, was directly attributable to a lack of awareness regarding the potential risks associated with apixaban and head trauma.
Rachel Hyman’s grief is compounded by the belief that her husband’s death was preventable. She stated, “Clive should and could have been saved. I have the extra trauma and burden that he should be alive. That is very hard to deal with. It should not have happened.” She firmly believes that had they been aware of the potential for a delayed brain hemorrhage following a head injury, they would have immediately sought medical attention. Her testimony highlights a critical gap in patient education and the potential consequences of inadequate warning labels.
The Coroner’s Warning and Concerns Over Patient Information
Assistant Coroner Sarah Bourke’s prevention of future deaths report explicitly stated that none of the patient information leaflets reviewed addressed the necessary steps to take after experiencing head trauma while on apixaban. This finding is particularly concerning given the widespread use of the drug. Apixaban is, according to the BBC, the most frequently prescribed direct-acting oral anticoagulant (DOAC) in England, with millions of prescriptions issued annually. The BBC reported that these drugs have saved thousands of lives each year, but also carry potential side effects.
The coroner’s report emphasizes the urgent need for clearer guidance for patients taking apixaban and similar medications. The lack of specific instructions regarding head injuries creates a dangerous ambiguity, potentially leading patients to underestimate the severity of a fall and delay seeking medical attention. This delay can be fatal, as tragically demonstrated in Clive Hyman’s case. The report’s recommendation for action aims to prevent similar deaths in the future by ensuring patients are fully informed about the risks and appropriate responses to head trauma.
Apixaban and the Risk of Bleeding: Understanding the Medication
Apixaban, marketed under the brand name Eliquis among others, is an anticoagulant medication used to prevent and treat blood clots. It works by inhibiting a specific clotting factor, Factor Xa, thereby reducing the risk of clot formation. As reported by Cambridge News, the medication is often prescribed for individuals with atrial fibrillation, a common heart condition that increases the risk of stroke. It is also used to prevent blood clots after hip or knee replacement surgery and to treat deep vein thrombosis (DVT) and pulmonary embolism (PE).
However, the very mechanism that makes apixaban effective – its ability to thin the blood – also creates a risk of bleeding. This risk is heightened when patients experience trauma, particularly head injuries. Even a seemingly minor fall can cause bleeding within the brain, which may not be immediately apparent. Symptoms can develop over days, as was the case with Clive Hyman, making early detection and treatment crucial. The delayed onset of symptoms underscores the importance of seeking immediate medical attention after any head injury while taking apixaban, regardless of how minor it may seem.
Rachel Hyman’s Campaign for Greater Awareness
Driven by her devastating loss, Rachel Hyman is now actively campaigning for increased awareness regarding the dangers of apixaban and the importance of seeking medical attention after a head injury. She believes that her husband’s death could have been avoided if they had been aware of the risks and emphasizes the need for clearer communication from healthcare providers and pharmaceutical companies. She is determined to prevent others from experiencing the same heartbreak.
“If you have a fall on blood thinners, even if you perceive fine, just go to the hospital,” Hyman implores. “They should be changing the advice.” Her call to action highlights the critical need for a proactive approach to patient safety, emphasizing that erring on the side of caution is paramount when dealing with medications that affect blood clotting. Hyman’s advocacy is gaining momentum, with many echoing her concerns about the adequacy of current patient information and the potential for preventable tragedies.
Key Takeaways
- Blood Thinners and Head Injuries: Patients taking blood thinners like apixaban are at increased risk of bleeding after a head injury, even if they feel fine.
- Delayed Symptoms: Bleeding in the brain can develop over days after a head injury, making immediate medical attention crucial.
- Inadequate Patient Information: Current patient information leaflets for apixaban do not adequately address the steps to take after a head injury.
- Advocacy for Change: Rachel Hyman is campaigning for clearer warnings and increased awareness to prevent similar tragedies.
The coroner’s office has yet to announce a follow-up hearing to assess whether pharmaceutical companies and healthcare providers have taken steps to address the concerns raised in the prevention of future deaths report. However, the case has already prompted renewed scrutiny of medication safety protocols and patient education materials. The outcome of this review will be critical in ensuring the safety of millions of patients taking blood-thinning medications worldwide.
This is a developing story. We will continue to monitor the situation and provide updates as they grow available. Share your thoughts and experiences in the comments below, and please share this article to help raise awareness about this important safety issue.